Eli Lilly and Co. (LLY) Stock Rating Reaffirmed by Jefferies Group
Several other research firms have also recently weighed in on LLY. Argus upped their price objective on Eli Lilly and from $90.00 to $95.00 and gave the stock a buy rating in a research report on Tuesday, August 2nd. Morgan Stanley reaffirmed a hold rating and set a $88.00 price objective on shares of Eli Lilly and in a research report on Saturday, June 4th. Zacks Investment Research upgraded Eli Lilly and from a hold rating to a buy rating and set a $92.00 target price on the stock in a report on Friday, August 5th. Leerink Swann reiterated a buy rating on shares of Eli Lilly and in a report on Sunday, June 26th. Finally, Credit Suisse Group AG reiterated a buy rating on shares of Eli Lilly and in a report on Tuesday, June 28th. Three research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. The stock presently has a consensus rating of Buy and an average price target of $96.85.
Shares of Eli Lilly and (NYSE:LLY) opened at 79.16 on Wednesday. Eli Lilly and has a one year low of $67.88 and a one year high of $88.48. The stock’s 50 day moving average price is $79.61 and its 200 day moving average price is $76.71. The firm has a market cap of $83.73 billion, a price-to-earnings ratio of 34.12 and a beta of 0.20.
Eli Lilly and (NYSE:LLY) last posted its quarterly earnings data on Tuesday, July 26th. The company reported $0.86 earnings per share for the quarter, hitting the consensus estimate of $0.86. The company earned $5.40 billion during the quarter, compared to analysts’ expectations of $5.14 billion. Eli Lilly and had a return on equity of 23.99% and a net margin of 11.97%. Eli Lilly and’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.90 earnings per share. On average, equities analysts anticipate that Eli Lilly and will post $3.59 earnings per share for the current fiscal year.
In other Eli Lilly and news, Director Jackson P. Tai bought 5,773 shares of Eli Lilly and stock in a transaction on Monday, August 15th. The shares were purchased at an average price of $80.43 per share, with a total value of $464,322.39. Following the acquisition, the director now owns 42,306 shares in the company, valued at approximately $3,402,671.58. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, major shareholder Lilly Endowment Inc sold 220,000 shares of the firm’s stock in a transaction on Wednesday, June 29th. The shares were sold at an average price of $77.86, for a total value of $17,129,200.00. Following the completion of the sale, the insider now directly owns 126,963,785 shares in the company, valued at approximately $9,885,400,300.10. The disclosure for this sale can be found here. 0.20% of the stock is owned by company insiders.
Several large investors have recently modified their holdings of LLY. Argent Trust Co increased its stake in shares of Eli Lilly and by 0.3% in the second quarter. Argent Trust Co now owns 4,184 shares of the company’s stock worth $329,000 after buying an additional 12 shares in the last quarter. Private Trust Co. NA increased its stake in shares of Eli Lilly and by 0.3% in the first quarter. Private Trust Co. NA now owns 5,384 shares of the company’s stock worth $387,000 after buying an additional 16 shares in the last quarter. MCF Advisors LLC increased its stake in shares of Eli Lilly and by 0.4% in the first quarter. MCF Advisors LLC now owns 3,918 shares of the company’s stock worth $282,000 after buying an additional 17 shares in the last quarter. Jackson Grant Investment Advisers Inc. increased its stake in shares of Eli Lilly and by 0.7% in the second quarter. Jackson Grant Investment Advisers Inc. now owns 3,905 shares of the company’s stock worth $308,000 after buying an additional 26 shares in the last quarter. Finally, Wagner Bowman Management Corp increased its stake in shares of Eli Lilly and by 0.3% in the second quarter. Wagner Bowman Management Corp now owns 9,672 shares of the company’s stock worth $761,000 after buying an additional 29 shares in the last quarter. 75.06% of the stock is currently owned by hedge funds and other institutional investors.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co. and related companies with MarketBeat.com's FREE daily email newsletter.